119 HR 5160 RH: Stem Cell Therapeutic and Research Reauthorization Act of 2025 U.S. House of Representatives 2026-07-02 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

IBUnion Calendar No. 629119th CONGRESS2d SessionH. R. 5160[Report No. 119–724]IN THE HOUSE OF REPRESENTATIVESSeptember 4, 2025Mr. Smith of New Jersey (for himself, Ms. Matsui, Mr. Bilirakis, Ms. Pingree, Ms. Tenney, and Mr. Mfume) introduced the following bill; which was referred to the Committee on Energy and CommerceJuly 2, 2026Additional sponsors: Mrs. Fischbach, Mrs. Dingell, Mr. Gottheimer, Mr. Aderholt, Ms. Malliotakis, Ms. Castor of Florida, Mr. Garbarino, Ms. Norton, Mr. Bentz, Ms. Barragán, Mr. Finstad, Ms. Morrison, Mr. Lawler, Mr. Vindman, Mr. Fitzpatrick, and Ms. Davids of KansasJuly 2, 2026Reported with an amendment, committed to the Committee of the Whole House on the State of the Union, and ordered to be printedStrike out all after the enacting clause and insert the part printed in italicFor text of introduced bill, see copy of bill as introduced on September 4, 2025A BILLTo reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes.

1.

Short title

This Act may be cited as the Stem Cell Therapeutic and Research Reauthorization Act of 2025.

2.

Reauthorization of the C.W. Bill Young Cell Transplantation Program

Section 379B of the Public Health Service Act (42 U.S.C. 274m) is amended—(1)by striking appropriated $31,009,000 and inserting the following:appropriated—(1)$31,009,000;(2)in paragraph (1), as so inserted, by striking the period at the end and inserting ; and; and(3)by adding at the end the following:(2)$33,009,000 for each of fiscal years 2027 through 2031..

3.

Cord blood inventory

(a)

In general

Section 2(a) of the Stem Cell Therapeutic and Research Act of 2005 (42 U.S.C. 274k note) is amended by striking at least 150,000 new units of high-quality cord blood and inserting a sufficient supply, as determined by the Secretary, of high-quality cord blood units. (b)

Application

Section 2(c) of such Act (42 U.S.C. 274k note) is amended—(1)in paragraph (2), by striking in perpetuity or; and(2)by amending paragraph (5) to read as follows:(5)if the Secretary determines through an assessment, or through petition by the applicant, that a cord blood bank is no longer operational, does not meet the requirements described in subsection (d)(4), or does not meet the requirements of section 379(d)(4) of the Public Health Service Act, and as a result may not distribute the high-quality units, the Secretary may transfer the units collected pursuant to this section to another qualified cord blood bank or entity approved by the Secretary to ensure continued availability of high-quality cord blood units..(c)

Duration of Contracts

Section 2(d)(4) of such Act (42 U.S.C. 274k note) is amended to read as follows:(4)

Consideration of best science

The Secretary shall take into consideration current scientific and clinical information in order to maximize the availability of high-quality cord blood units meeting applicable clinical and quality standards for transplant when entering into contracts under this section, or when extending a period of funding under such a contract under paragraph (2)..(d)

Inventory management

Section 2 of such Act (42 U.S.C. 274k note) is amended—(1)by redesignating subsections (e), (f), and (g) and as subsections (f), (g), and (h), respectively; and(2)by inserting after subsection (d) the following:(e)

Inventory management

(1)

In general

The Secretary shall manage the size and composition of the National Cord Blood Inventory to maximize clinical utility, ensure genetic diversity, and promote the efficient use of resources.(2)

Considerations

In carrying out paragraph (1), the Secretary may—(A)on the Secretary’s own initiative or upon petition by a qualified cord blood bank, make determinations regarding the continued storage of cord blood units based on the best available scientific and clinical evidence; or(B)prioritize the collection, retention, or disposition of cord blood units based on scientific, clinical, or operational considerations that the Secretary determines to be relevant..(e)

Definitions

Section 2(g) of such Act, as redesignated by subsection (d)(1) of this section, is amended—(1)by redesignating paragraphs (4) and (5) as paragraphs (5) and (6), respectively; and(2)by inserting after paragraph (3) the following:(4)The term high quality cord blood unit means a cord blood unit that meets current industry standards and any requirements of the Food and Drug Administration..(f)

Authorization of appropriations

Section 2(h) of such Act, as redesignated by subsection (d)(1) of this section, is amended by striking fiscal years 2022 through 2026 and inserting fiscal years 2027 through 2031.

July 2, 2026Reported with an amendment, committed to the Committee of the Whole House on the State of the Union, and ordered to be printed